Q-omics provides the consensus-scored MTLN profile across patient tissues and cancer cell-line models. MTLN expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MTLN is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, MTLN RNA expression shows 16,376 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KICH, and THYM as cancer lineages where MTLN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTLN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTLN survival associations across molecular data types. MTLN RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTLN RNA expression–survival associations across cancer types. High MTLN expression shows unfavorable associations in UCS, KIRC, ACC, UVM and LGG, but favorable associations in ESCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MTLN RNA expression.
This table summarizes MTLN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MTLN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTLN shows lower tumor expression in KICH and HNSC and higher tumor expression in COAD, KIRP, LIHC and KIRC. The KICH box plot shows higher MTLN RNA expression in normal versus tumor tissue (log2 FC = −1.563, t-test p < 0.001).
This table shows molecular features associated with MTLN in patient tissues and cancer cell lines. In patient samples, MTLN shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTLN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
